Abstracts tagged "rheumatic disease and artificial intelligence"

Abstract Number: 2060 • 2019 ACR/ARP Annual Meeting
The Current State of Big Data Use and Artificial Intelligence in RMDs: A Systematic Literature Review Informing EULAR Recommendations
Joanna Kedra¹, Timothy R.D. Radstake ², Aridaman Pandit ³, Xenofon Baraliakos ⁴, Francis Berenbaum ⁵, Axel Finckh ⁶, Bruno Fautrel ⁷, Tanja Stamm ⁸, David Gomez-Cabrero ⁹, Christian Pristipino ¹⁰, Remy Choquet ¹¹, Hervé Servy ¹², Simon Stones ¹³, Gerd Burmester ¹⁴ and Laure Gossec ¹⁵, ¹Sorbonne Université, Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), UMR S1136, Paris France, Paris, France, ²Department of Rheumatology/Clinical Immunology, University Medical Center Utrecht, Utrecht, The Netherlands., Utrecht, Netherlands, ³Dept. of Rheumatology, Clinical Immunology and Laboratory for Translational Immunology, University Medical Center Utrecht, The Netherlands, Utrecht, Netherlands, ⁴Rheumazentrum Ruhrgebiet-Ruhr-University Bochum, Herne, Germany, Herne, Germany, ⁵Sorbonne Université-Inserm CDR Saint-Antoine, AP-HP, Paris, France, ⁶Division of Rheumatology, Geneva University Hospital, Switzerland, Geneva, Switzerland, ⁷Pitié-Salpêtrière Hospital, Department of Rheumatology, AP-HP, Sorbonne University, UPMC university, Paris, Ile-de-France, France, ⁸Medical University of Vienna, Vienna, Austria, ⁹Translational Bioinformatics Unit, Navarra Biomed, Departamento de Salud-Universidad Pública de Navarra, Pamplona, Navarra, Spain, Pamplona, Spain, ¹⁰Ospedale San Filippo Neri, Rome, Italy., Rome, Italy, ¹¹INSERM U1142, Orange Healthcare, France, Paris, France, ¹²Sanoia e-health services, France, Paris, France, ¹³School of Healthcare, University of Leeds, Leeds, UK, Leeds, United Kingdom, ¹⁴Charité—University Medicine Berlin, Berlin, Germany, ¹⁵Sorbonne Université and Hôpital Pitié-Salpêtrière, Paris, France
Background/Purpose: Big data are defined as data sets that are too large or complex for traditional data-processing application software to adequately deal with. Artificial Intelligence…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].